A Phase I, Open Label, Randomized, Three Period, One-Way, Two Cohort, Adaptive Crossover Study to Evaluate the Effect of Darunavir/Ritonavir Plus Etravirine and Lopinavir/Ritonavir Plus Etravirine on GSK1349572 Pharmacokinetics in Healthy Adult Subjects (ING112934).
Phase of Trial: Phase I
Latest Information Update: 21 Feb 2012
At a glance
- Drugs Darunavir; Dolutegravir; Etravirine; Lopinavir/ritonavir; Ritonavir
- Indications HIV infections; HIV-1 infections
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 21 Feb 2012 Company added in association field as reported by ClinicalTrials.gov.
- 16 Jun 2009 Actual end date (May 2009) added as reported by ClinicalTrials.gov.
- 16 Jun 2009 Actual patient number (17) added as reported by ClinicalTrials.gov.